Clinician’s guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer
The introduction of the cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib to the adjuvant setting marks a significant advancement in the treatment of hormone-receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer (HR+, HER2− EBC). Despi...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2025-03-01
|
| coleção: | Therapeutic Advances in Medical Oncology |
| Acesso em linha: | https://doi.org/10.1177/17588359251326710 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|